Table 6 Univariate analysis of the impact of expression of serine/glycine metabolism-related proteins in breast cancers on disease-free survival and overall survival by the log-rank test
Parameter | Number of patients/recurrence/death | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | ||
GNMT | Â | Â | 0.042 | Â | 0.498 |
  Negative | 664/54/55 | 127 (123–130) |  | 129 (127–132) |  |
  Positive | 57/9/6 | 98 (91–106) |  | 126 (116–135) |  |
SARDH | Â | Â | 0.767 | Â | 0.264 |
  Negative | 597/53/47 | 126 (122–130) |  | 130 (127–133) |  |
  Positive | 124/10/14 | 121 (115–127) |  | 124 (117–132) |  |
PIPOX (T) | Â | Â | 0.039 | Â | 0.361 |
  Negative | 570/57/52 | 126 (123–129) |  | 129 (126–131) |  |
  Positive | 151/6/9 | 123 (117–129) |  | 131 (126–135) |  |
PIPOX (S) | Â | Â | 0.927 | Â | 0.636 |
  Negative | 671/59/58 | 126 (122–130) |  | 129 (126–132) |  |
  Positive | 50/4/3 | 122 (114–130) |  | 126 (119–132) |  |
Sarcosine metabolic type | Â | Â | 0.021 | Â | 0.503 |
High sarcosine type | 36/8/5 | 90 (79–101) |  | 118 (106–130) |  |
Intermediate sarcosine type | 21/1/1 | 108 (102–114) |  | 132 (122–143) |  |
Low sarcosine type | 219/15/20 | 120 (115–125) |  | 126 (121–132) |  |
Null type | 445/39/35 | 127 (124–131) |  | 130 (127–133) |  |